Free Alerts   Login
Health Care › Pharmaceutical Preparations

COLL Stock Price Correlated With Collegium Pharmaceutical Financials

COLL Stock Price vs. Quarterly
COLL
Income Statement
Cash Flow
Balance Sheet

COLL Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

COLL Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

COLL Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
5,786,993 sh
-453,971 sh
-7%
$178,123
$38,636
Rubric Capital Management Lp
2,758,253 sh
-416,747 sh
-13%
$84,899
$13,938
Eventide Asset Management
2,630,478 sh
-856 sh
0%
$80,966
$22,156
Vanguard Group
2,312,786 sh
-26,310 sh
-1%
$71,188
$18,909
Pacer Advisors.
2,174,718 sh
883,380 sh
68%
$66,938
$38,077
Principal Financial Group
1,569,151 sh
-10,089 sh
-1%
$48,298
$13,001
Invesco.
1,441,617 sh
282,013 sh
24%
$44,373
$18,457
Renaissance Technologies
1,384,598 sh
212,000 sh
18%
$43
$17
State Street
1,313,875 sh
23,379 sh
2%
$40,441
$11,598
Camber Capital Management Lp
1,050,000 sh
 
$32,319
Dimensional Fund Advisors
1,039,218 sh
29,529 sh
3%
$31,988
$9,420
Morgan Stanley
1,001,751 sh
413,286 sh
70%
$30,834
$17,682
Geode Capital Management
731,266 sh
20,382 sh
3%
$22,511
$6,621
Victory Capital Management
723,297 sh
-24,974 sh
-3%
$22,263
$5,539
Emerald Advisers
666,096 sh
-24,391 sh
-4%
$20,502
$5,070
Massachusetts Financial Services /Ma/
665,118 sh
599 sh
0%
$20,472
$5,620
Janus Henderson Group Plc
627,512 sh
-252,686 sh
-29%
$19,316
-$356
Rock Springs Capital Management Lp
562,000 sh
-88,000 sh
-14%
$17,298
$3,329
Emerald Mutual Fund Advisers Trust
551,794 sh
-7,686 sh
-1%
$16,984
$4,480
Millennium Management
443,645 sh
-39,328 sh
-8%
$13,655
$2,861
COMPANY PROFILE
1. NATURE OF BUSINESS Organization Collegium Pharmaceutical, Inc. (the “Company”) was incorporated in Delaware in April 2002 and then reincorporated in Virginia in July 2014. The Company has its principal operations in Stoughton, Massachusetts. The Company’s mission is to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company’s first product, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone. In April 2016, the United States Food and Drug Administration (the “FDA”) approved the Company’s new drug application (“NDA”) for Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. In June 2016, the Company announced the commercial launch of Xtampza ER. The Company’s product portfolio also includes Nucynta ER and Nucynta IR (the “Nucynta Products”). In December 2017, the Company entered into a Commercialization Agreement (the “Nucynta Commercialization Agreement”) with Assertio Therapeutics, Inc. (formerly known as Depomed) (“Assertio”), pursuant to which the Company acquired the right to commercialize the Nucynta Products in the United States. The Company began shipping and recognizing product sales on the Nucynta Products on January 9, 2018 and began marketing the Nucynta Products in February 2018. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. Nucynta IR is an immediate-release formulation of tapentadol that is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. On February 6, 2020, the Company entered into an Asset Purchase Agreement with Assertio (the “Nucynta Purchase Agreement”), pursuant to which the Company agreed to acquire from Assertio certain assets related to the Nucynta Products (the “Nucynta Acquisition”), including the license from Grünenthal GmbH (“Grünenthal”), for an aggregate purchase price of $375,000, subject to certain closing and post-closing adjustments as described in the Nucynta Purchase Agreement. On February 13, 2020, the Company closed the Nucynta Acquisition in accordance with the Nucynta Purchase Agreement. Upon closing, the Nucynta Commercialization Agreement was effectively terminated. Following the closing, the Company's prior royalty obligation to Assertio ceased and the Company’s only remaining royalty obligation is to pay 14% of net sales of the Nucynta Products directly to Grünenthal. The Company periodically reviews its accounting estimates in light of changes in circumstances, facts and experience. As of the date of the filing of this Annual Report on Form 10-K, the Company expects the COVID-19 pandemic and actions taken to contain it to continue to impact its revenue. Notwithstanding the lifting of COVID-19 restrictions in many jurisdictions, and amidst continuing public health concerns relating to the spread of COVID-19, weekly pain patient office visits continue to be depressed compared to pre-COVID periods, which in turn may account for fewer patients beginning therapy with the Company’s products. The Company believes that the disruptions caused by COVID-19 will continue and there remains substantial uncertainty as to when such disruptions will cease. ​ The Company’s operations are subject to certain risks and uncertainties. The principal risks include inability to continue successfully commercializing products, changing market conditions for products and development of competing products, changing regulatory environment and reimbursement landscape, litigation related

Free historical financial statements for Collegium Pharmaceutical Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 30 quarters since 2016. Compare with COLL stock chart to see long term trends.

Data imported from Collegium Pharmaceutical Inc SEC filings. Check original filings before making any investment decision.